Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report Scope and Overview:

The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market was valued at USD 1.51 Billion in 2025 and is projected to reach USD 5.95 Billion by 2035, registering a CAGR of 14.8% from 2026 to 2035.

The PPMS Treatment Market continues expanding as ocrelizumab remains the only broadly approved disease-modifying therapy for this progressive, difficult-to-treat form of multiple sclerosis, while an active late-stage pipeline of BTK inhibitors and next-generation monoclonal antibodies continues seeking to expand treatment options. The market is characterized by intensifying clinical trial activity targeting disability progression independent of relapse activity, growing interest in higher-dose and subcutaneous reformulations that reduce infusion burden, and expanding diagnostic awareness that continues improving earlier PPMS identification. Significant growth is being witnessed in monoclonal antibody development and intravenous-to-subcutaneous conversion therapies, as neurologists and patients increasingly prioritize treatments offering meaningful disability-progression benefit with more convenient administration.

Sanofi announced in December 2025 that tolebrutinib did not meet its primary endpoint in the Phase 3 PERSEUS study evaluating disability progression delay in PPMS patients, leading the company to discontinue its pursuit of PPMS approval for the oral BTK inhibitor, underscoring the continued clinical difficulty of developing effective PPMS-specific therapies.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends

• Rising late-stage pipeline activity in BTK inhibitors continues targeting progression independent of relapse activity.

• Growing development of subcutaneous reformulations continues reducing infusion-related treatment burden.

• Expanding diagnostic awareness and earlier identification continues broadening the treatable patient population.

• Increasing monoclonal antibody development continues diversifying the PPMS therapeutic landscape.

• Rising specialty pharmacy and infusion-center coordination continues improving treatment access and adherence.

U.S. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Outlook

The U.S. PPMS Treatment Market was valued at approximately USD 0.57 Billion in 2025 and is projected to reach approximately USD 2.23 Billion by 2035, registering a CAGR of approximately 14.6% from 2026 to 2035.

Demand across the United States continued to be shaped by ocrelizumab's established position as the only FDA-approved PPMS-specific disease-modifying therapy, extensive neurology specialty infrastructure, and strong insurance coverage supporting high-cost biologic treatment access. The use of subcutaneous ocrelizumab-hyaluronidase formulation, which reduces infusion times, reinforces the position of the US as the world leader when it comes to the market for PPMS treatment. Growing interest among academics and patients alike in clinical trials conducted in major centers of medical learning leads to the creation of additional demand domestically. Growing development of programs providing support to patients also helps to offset costs related to the expensive biologics therapy.

The FDA approved OCREVUS ZUNOVO, a subcutaneous formulation of ocrelizumab combined with Halozyme's ENHANZE drug-delivery technology, enabling a twice-yearly, approximately 10-minute subcutaneous injection for relapsing and primary progressive multiple sclerosis, substantially reducing the administration burden compared with the original two-hour intravenous infusion.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segment Analysis

• By Drug Type, Monoclonal Antibodies segment dominated the PPMS Treatment Market in 2025 with 68% share; Other Drug Types segment is the fastest growing segment with a CAGR of approximately 17.2%.

• By Route of Administration, Intravenous segment dominated the PPMS Treatment Market in 2025 with 61% share; Oral segment is the fastest growing segment with a CAGR of approximately 18.6%.

• By Distribution Channel, Hospital Pharmacies segment dominated the PPMS Treatment Market in 2025 with 47% share; Online Pharmacies segment is the fastest growing segment with a CAGR of approximately 16.4%.

By Drug Type: Monoclonal Antibodies Lead, Emerging Drug Classes Grow Fastest

The Monoclonal Antibodies segment dominated the PPMS Treatment Market in 2025, anchored almost entirely by ocrelizumab's position as the sole broadly approved PPMS-specific disease-modifying therapy, alongside off-label and investigational use of related CD20-targeting agents such as rituximab and ofatumumab. Sustained clinical evidence supporting B-cell depletion's disability-progression benefit continues reinforcing this segment's leading contribution to total drug-type revenue, reinforced by growing physician confidence in monoclonal antibody safety profiles built over nearly a decade of real-world PPMS treatment experience.

Other Drug Types, encompassing investigational BTK inhibitors and emerging mechanisms of action, are the fastest growing as an active late-stage pipeline continues pursuing approval despite recent clinical setbacks. Immunosuppressants and Corticosteroids continue contributing modest, largely symptomatic and off-label supportive care demand, with genuine disease-modifying benefit in PPMS remaining concentrated almost entirely within the monoclonal antibody class at present, though ongoing research continues exploring combination and adjunctive treatment approaches.

By Route of Administration: Intravenous Leads, Oral Formulations Grow Fastest

Intravenous administration dominated the PPMS Treatment Market in 2025, because ocrelizumab, the market's dominant therapy, has historically been delivered via twice-yearly intravenous infusion requiring clinical supervision at specialized infusion centers. Extensive established infusion-center infrastructure and physician familiarity with intravenous monoclonal antibody administration sustained this route's dominant contribution to total revenue throughout the base year, reinforced by continued reliance on infusion-based delivery across the large majority of currently treated PPMS patients globally.

Oral formulations are the fastest growing route as BTK inhibitor pipeline candidates, despite recent trial setbacks, continue representing the most active area of oral disease-modifying therapy development for progressive MS subtypes. Other Routes, including emerging subcutaneous delivery, continue gaining momentum following recent approval of subcutaneous ocrelizumab-hyaluronidase formulations that substantially reduce administration time compared with traditional intravenous infusion protocols, a shift patients and clinicians alike have welcomed for its convenience.

By Distribution Channel: Hospital Pharmacies Lead, Online Pharmacies Emerge Fastest-Growing

Hospital Pharmacies dominated the PPMS Treatment Market in 2025 given their central role in dispensing and administering infusion-based monoclonal antibody therapies requiring clinical supervision and specialized handling protocols. Extensive coordination between neurology departments and hospital-based infusion centers sustained this segment's dominant contribution to total distribution-channel revenue throughout the base year, reinforced by insurance and reimbursement structures that frequently channel high-cost biologic therapies through hospital-affiliated specialty pharmacy networks.

Online Pharmacies are the fastest growing as specialty pharmacy digital platforms increasingly coordinate at-home delivery logistics for supportive medications and, with growing subcutaneous formulation availability, potentially self-administered future therapies. Retail Pharmacies continue contributing steady demand primarily for symptomatic and supportive care medications, with growing digital prescription coordination further supporting patient convenience across the broader PPMS treatment journey, particularly for patients managing multiple concurrent medications.

Regional Analysis

North America PPMS Treatment Market Insights

North America dominated the PPMS Treatment Market with the largest revenue share of approximately 44.5% in 2025. Extensive neurology specialty infrastructure, ocrelizumab's established position as the region's primary approved therapy, and strong insurance coverage supporting high-cost biologic access continued reinforcing this dominant regional position. Robust clinical trial infrastructure and concentration of leading academic medical centers gave regional patients consistent access to investigational PPMS therapies well ahead of most other regions, with several leading biopharmaceutical companies headquartered within the region further reinforcing early trial access.

The United States accounted for the substantial majority of regional revenue, anchored by extensive specialty neurology infrastructure and a high concentration of academic medical centers conducting late-stage PPMS clinical research. Canada added further demand through its own well-funded national health system and growing neurology specialty capacity, and that combined strength kept the continent the largest addressable market for PPMS therapy vendors through the forecast period, supported by continued pipeline investment despite recent high-profile trial setbacks.

Europe PPMS Treatment Market Insights

Europe held a meaningful share of global revenue, supported by well-established public healthcare systems providing broad access to ocrelizumab, strong neurology research networks, and continued regulatory engagement on pipeline candidates including tolebrutinib. Regulatory harmonization under EMA frameworks and sustained academic research investment continued lowering historically significant barriers to advanced PPMS therapy adoption across the continent's national health systems.

Germany led demand at roughly 20.30% of European revenue, supported by its extensive neurology specialty infrastructure and strong reimbursement coverage for advanced biologic therapies among the region's largest economies, several of which also host major global pharmaceutical company headquarters. The UK and France contributed substantial additional demand through their own well-funded national health systems and active participation in multinational PPMS clinical trials, and continued European investment in neurology research infrastructure should keep regional demand for PPMS therapies climbing steadily through the forecast period.

Asia Pacific PPMS Treatment Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 17.8% from 2026 to 2035. The drivers of this growth include greater support from the government, increased investments in the biotechnology industry, increase in diagnosis capabilities of neurology in China and Japan, and the rising awareness of primary-progressive multiple sclerosis as a separate disease entity. In addition to this, the rapid expansion of specialized healthcare facilities in the region will add to the target patient pool.

China held a substantial share of regional revenue, supported by rapid expansion of neurology diagnostic and specialty treatment infrastructure alongside rising government biotech investment. India and Japan contributed meaningful additional demand, with India's growing neurology specialty capacity and Japan's advanced diagnostic infrastructure both reinforcing the region's position as the fastest-growing market tracked in this report, with all three countries expected to hold the major share of regional revenue through the forecast period as diagnostic access and specialty pharmaceutical distribution capacity continue to scale rapidly.

MEA and Latin America PPMS Treatment Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by expanding neurology specialty infrastructure investment, rising government healthcare modernization spending, and growing awareness of PPMS diagnosis and treatment options across both areas. As these markets continued building out modern neurology infrastructure, access to ocrelizumab and supportive PPMS treatment proved a genuinely meaningful way to expand disease-modifying therapy availability without the extensive specialty infrastructure wealthier nations historically required.

Saudi Arabia led Middle East and Africa demand, supported by the country's substantial healthcare infrastructure investment under its national health-sector transformation programs and expanding neurology specialty capacity. The UAE contributed further demand through its own expanding private specialty healthcare network, having also approved tolebrutinib for related progressive MS use. In Latin America, Brazil accounted for the largest share of regional revenue, with growing neurology infrastructure and rising diagnostic awareness continuing to anchor regional demand for PPMS treatment.

Market Dynamics

Growth Drivers: Expanding Pipeline Investment and Growing Diagnostic Awareness

The industry is driven by ocrelizumab's established clinical efficacy anchoring the current standard of care, continued late-stage pipeline investment in BTK inhibitors and next-generation monoclonal antibodies despite recent setbacks, growing diagnostic awareness improving earlier PPMS identification, and expanding development of subcutaneous formulations reducing infusion burden. As neurologists continue seeking treatments offering meaningful disability-progression benefit with improved administration convenience, the need for advanced PPMS therapies continues driving demand across hospital, specialty clinic, and infusion-center settings worldwide.

Rising global neurology specialty infrastructure investment continues reinforcing this driver, as expanding diagnostic capacity across both established and emerging healthcare markets increasingly identifies PPMS patients earlier in disease progression when treatment intervention offers the greatest potential benefit. Continued academic and industry collaboration on biomarker research is also supporting earlier, more precise diagnosis across specialty neurology centers. Growing pharmaceutical industry commitment to progressive MS research, despite recent high-profile trial disappointments, continues sustaining innovation investment, and that combination of clinical need and sustained pipeline activity is exactly what keeps demand climbing at such a steady, sustained pace across the global PPMS treatment landscape.

Restraints: Limited Treatment Options and High Biologic Therapy Costs

The persistently narrow range of approved PPMS-specific therapies, with ocrelizumab remaining the only broadly approved disease-modifying option nearly a decade after its initial approval, continues posing a genuine restraint on market expansion, particularly given the disappointing PERSEUS trial results and Sanofi's subsequent decision to discontinue tolebrutinib's PPMS pursuit. That treatment scarcity has kept many patients without disease-modifying options beyond a single therapeutic class, leaving significant unmet need across the broader progressive MS population.

The substantial cost of biologic monoclonal antibody therapy continues posing a further restraint, as high per-patient treatment expenses create significant reimbursement and access challenges across both developed and developing healthcare markets with varying insurance coverage structures. That cost burden keeps some healthcare systems limiting ocrelizumab access to patients meeting strict eligibility criteria, relying on more conservative prescribing protocols rather than expanding treatment access at the pace unmet clinical need would otherwise support.

Opportunities: Next-Generation Pipeline Candidates and Subcutaneous Delivery Expansion

The investment in next-generation monoclonal antibodies and other mechanism of action continues to provide an excellent chance. The PPMS pipeline continues to advance with drugs such as fenebrutinib, despite tolebrutinib being a little behind, demonstrating the industry’s ongoing efforts to expand the limited existing therapy options. Early entrants in the market with PPMS drugs based on novel mechanism of action will benefit immensely in capturing the market share.

Expanding subcutaneous and self-administered delivery formats offers a second substantial opportunity, as reduced infusion-center dependency continues improving patient convenience and potentially expanding treatment access across regions with limited specialty infusion infrastructure. Vendors with proven, convenient delivery platforms stand to capture meaningful share as healthcare systems increasingly prioritize treatment approaches that reduce administration burden while maintaining established clinical efficacy standards.

Recent Developments:

• December 2024: Tolebrutinib received FDA Breakthrough Therapy Designation, reflecting continued regulatory interest in BTK inhibitor mechanisms for progressive multiple sclerosis despite later PPMS trial setbacks.

• 2025: The Emirates Drug Establishment approved tolebrutinib for non-relapsing secondary progressive multiple sclerosis in the United Arab Emirates, marking an early regulatory approval for the BTK inhibitor class in progressive MS.

• 2025: Roche continued advancing its Phase 3 FENhance study evaluating fenebrutinib against ocrelizumab in PPMS patients, representing one of the most closely watched next-generation candidates in the pipeline.

• December 2025: The FDA issued a complete response letter declining approval of tolebrutinib for nonrelapsing secondary progressive MS, with Sanofi stating it will work with the agency to find a path forward for the therapy.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market key players are:

• F. Hoffmann-La Roche Ltd (Genentech)

• Sanofi S.A.

• Novartis AG

• Biogen Inc.

• Bristol Myers Squibb Company

• Merck KGaA

• Johnson & Johnson (Janssen Pharmaceuticals)

• TG Therapeutics, Inc.

• Immunic, Inc.

• Halozyme Therapeutics, Inc.

• Mapi Pharma Ltd.

• InnoCare Pharma Limited

• Horizon Therapeutics plc (Viela Bio)

• Teva Pharmaceutical Industries Ltd.

• MedDay Pharmaceuticals SA

• Genzyme Corporation

• Alkahest, Inc.

• Contineum Therapeutics, Inc.

• Actelion Pharmaceuticals Ltd.

• Population Health Partners (PHP MS Ventures)

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report Scope: